Do you want to read an article? Please log in or register.
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study
Central Nervous System Tumors
Related content
Central Nervous System Tumors
Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group
Neuro Oncol
Mazewski C, Leary SES, Kang G, Li BK, Kellie S, Hayes L, Shaw D, Ho B, Reddy A, Gossett J, Burger PC, Judkins AR, Aridgides P, Geyer JR, Gajjar A, Pollack IF, Fouladi M, Huang A
doi: 10.1093/neuonc/noaf132
Sarcoma
Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus Statement
J Natl Compr Canc Netw
Dietz MS, Al-Ibraheemi A, Davis JL, Hawkins CM, Craig BT, Dasgupta R, Geller DS, Shulman DS, Cohen-Gogo S, Gupta A, Whiteway SL, Slotkin EK, Heske CM, Ahmed SK, Indelicato DJ, Albert CM, Montgomery N, Sandberg JK, Grier HE, Krailo M, Isakoff MS, Rubin E, Lawlor ER, DuBois SG, Mascarenhas L, Grohar PJ, Binitie O, Reed D, Janeway K, Roberts RD, Bailey KM
doi: 10.6004/jnccn.2024.7063
ASH 2024
Lymphoma
AALL1731: Blinatumomab significantly improves DFS in children with standard-risk B-ALL
Sarcoma
Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 Trial
J Clin Oncol
Bisogno G, Chisholm J, Hladun R, De Salvo GL, Guerin F, Casanova M, Mandeville H, Alaggio R, Coppadoro B, Orbach D, Ferrari A, van Rijn R, Defachelles AS, Ben-Arush M, Glosli H, Cesen M, Merks JHM, Minard-Colin V
doi: 10.1200/JCO-24-02850
ASH 2024
Multiple Myeloma (MM)
AQUILA: Daratumumab significantly improves PFS in high-risk smoldering multiple myeloma
Further Publications
Clinical and molecular risk factors in extracranial malignant rhabdoid tumors - Towards an integrated model of high-risk tumors
Clin Cancer Res
Fincke VE, Steinbügl M, Chun HE, Nemes K, Mucha M, Loßner M, Dorn F, Gastberger K, Bühner S, Sill M, Kröncke T, Siebert R, Melchior P, Furtwängler R, Schlesner M, Vokuhl C, Rocken C, Johann PD, Frühwald MC
doi: 10.1158/1078-0432.CCR-23-3489
Multiple Myeloma (MM)
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database
Blood Cancer J
Rajkumar SV, Mateos MV, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, Lam A, Carson R, Dennis R, Kaila S, Matt K, Duran J, Lonial S
doi: 10.1038/s41408-024-01170-z
Lymphoma
Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group
Leukemia
Eichenauer DA, Basaran A, Bühnen I, Fuchs M, von Tresckow B, Rosenwald A, Hansmann ML, Bernd HW, Borchmann P, Klapper W, Hartmann S
doi: 10.1038/s41375-025-02641-3
COMMENTED
Genitourinary Cancer
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
BJU Int
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, Soria F, Álvarez-Maestro M, Bazán AA, Pradere B, Klatte T, Contieri R, Hurle R, Krajewski W, Subiela JD, Pichler R, Szostek A, Marcq G, Elena JLR, Aranda J, Gontero P, Rouprêt M, Shariat SF, Necchi A, Montorsi F, Briganti A, Xylinas E, Moschini M, EuroGemDoce Study Group Collaborators, European Association of Urology ‐ Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group
doi: 10.1111/bju.16645